Overview

* CytomX Q2 2025 revenue of $18.7 mln beats analyst expectations, per LSEG data

* Operating expenses decreased due to reduced R&D costs and program de-prioritization

* Completed $100 mln stock offering, raising cash position to $158.1 mln

* Announced positive interim data for CX-2051 in advanced colorectal cancer

Outlook

* Company expects CX-2051 Phase 1 data update by Q1 2026

* CytomX plans CX-2051 Phase 2 study initiation in 1H 2026

* Company anticipates CX-801 combination therapy data in 2026

* CytomX sees cash runway extending to Q2 2027

Result Drivers

* POSITIVE CLINICAL DATA - Positive interim data from CX-2051 Phase 1 study in advanced colorectal cancer announced

* DOSE EXPANSIONS - Initiated dose expansions for CX-2051 at multiple dosage levels

* FINANCIAL STRENGTH - Completed $100 mln stock offering, enhancing cash position to support R&D

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $18.66 $14.80

Revenue mln mln (5

Analysts

)

Q2 Net -$154,00

Income 0

Q2 Cash $158.10

& mln

Investme

nts

Q2 $19.94

Operatin mln

g

Expenses

Q2 -$1.29

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for CytomX Therapeutics Inc ( CTMX ) is $5.50, about 60.5% above its August 6 closing price of $2.17

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)